https://www.selleckchem.com/pr....oducts/hmpl-504-azd6
Because of the higher incidence of DLTs, the niraparib-apalutamide combination and niraparib 300mg combination with AAP were not further evaluated. Niraparib 200mg was selected as the RP2D with AAP. Of 19 patients receiving niraparib 200mg with AAP, 12 (63.2%) had grade 3/4 treatment-emergent adverse events, the most common being thrombocytopenia (26.3%) and hypertension (21.1%). Five patients (26.3%) had adverse events leading to treatment discontinuation. These results support the choice of niraparib 200mg as the RP
Like
Comment
Share
